The FDA has granted a fast track designation to AMG 510 for the treatment of patients with KRAS G12C–mutated metastatic non–small cell lung cancer who received prior therapy.
The FDA has granted a fast track designation to the investigational KRAS inhibitor AMG 510 for the treatment of patients with KRAS G12C—mutated non–small cell lung cancer (NSCLC) who have received prior treatment.1
The decision is based on updated phase I data that were recently presented during the 2019 World Conference on Lung Cancer, which showed that AMG 510 elicited a 100% disease control rate (DCR) at the target dose in evaluable patients with KRAS G12C—mutant NSCLC.2
“There is a need for targeted treatments for specific driver mutations of cancer that do not have an approved therapy,” Ramaswamy Govindan, MD, principal investigator and professor at the Washington University School of Medicine in St. Louis, stated in a press release and who also presented the updating findings during this year's conference. “These data continue to show encouraging antitumor activity with AMG 510, underscoring the potential to close the treatment gap for patients with previously treated KRAS G12C—mutated NSCLC.”
AMG 510 is a first-in-class investigational agent that selectively and irreversibly targets the KRAS G12C protein. The phase I dose-escalation/expansion study was conducted in patients with previously treated solid tumors who harbor a KRAS G12C mutation. The updated data presented at the 2019 World Conference on Lung Cancer focused on additional follow-up among patients with NSCLC from the data that were originally presented at the 2019 ASCO Annual Meeting.
The findings covered 34 patients with NSCLC treated with AMG 510, including 19 who were treated in the dose-escalation phase with doses starting at 180 mg and 15 who were treated in the expansion phase at the determined phase II dose of 960 mg once daily.
No dose-limiting toxicities were observed among the patients with NSCLC and although 4 patients discontinued treatment, none discontinued due to adverse events. Twenty-seven patients remained on treatment at the time of data cutoff.
Among 23 evaluable patients who had completed the first 6-week CT scan or had early progressive disease, the objective response rate was 48% and the DCR was 96%. Thirteen of these patients received the phase II dose of 960 mg, and of these patients, 7 (54%) achieved a partial response and 6 (46%) achieved stable disease.
“These new data reinforce the earlier positive response rate we shared at ASCO in more non-small cell lung cancer patients receiving AMG 510,” David M. Reese, MD, executive vice president of research and development at Amgen, the developer of AMG 510, stated in the press release. “We remain enthusiastic about the promise of AMG 510 and continue to rapidly advance its development program both as monotherapy and in combination.”
Grade 1/2 treatment-related adverse events (TRAEs) were observed in 26.5% of patients and grade 3 TRAEs included anemia and diarrhea (8.8% each). No grade ≥4 TRAEs were reported.
Additional findings from the phase I study will also be presented at the 2019 ESMO Congress.